<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337632</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1303703</org_study_id>
    <nct_id>NCT04337632</nct_id>
  </id_info>
  <brief_title>Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum—Partial Sensitive Recurrent Ovarian Cancer</brief_title>
  <official_title>Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum—Partial Sensitive Recurrent Ovarian Cancer Based on 11 Gene Tests of Homologous Recombination Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, prospective, randomized studies.Evaluation of the sensitivity to different
      chemotherapy regimens in platinum—partial sensitive recurrent ovarian cancer based on 11 gene
      tests of homologous recombination pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients meeting the following inclusion criteria were randomly divided into two groups in a
      1:1 ratio: paclitaxel/platinum chemotherapy group (TP) and Doxorubicin Hydrochloride Liposome
      Injection/platinum chemotherapy group (PP) (the specific chemotherapy regimens are as
      follows.Chemotherapy to tumor progression or adverse reactions can not be tolerated,
      effective chemotherapy patients with a maximum of 6 cycles of chemotherapy.The primary
      endpoint was progression-free survival (PFS), and the secondary endpoints were safety and
      overall survival.Also USES the next-generation sequencing (NGS) method to detect patients
      with recurrence after tumor tissues (including chest, ascites, homologous recombination
      pathway in the tumor tissue and peripheral blood ctDNA 11 genetic mutations, rearrangement,
      and so on and so forth, whether patients with analysing the homologous recombination pathways
      for paclitaxel/platinum chemotherapy or Doxorubicin Hydrochloride Liposome Injection/platinum
      chemotherapy has different sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS（Progression-Free-Survival)</measure>
    <time_frame>up to 24months</time_frame>
    <description>From the date of randomization to the time of tumor progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS(Overall survival)</measure>
    <time_frame>up to 36months</time_frame>
    <description>Time from random day to death (month)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR( Objective response rate)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>the percentage of patients whose tumors shrink a certain amount and stay that way for a certain amount of time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">338</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>PP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, day 1, intravenous drip, repeated every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride Liposome Injection+carboplatin</intervention_name>
    <description>Doxorubicin Hydrochloride Liposome Injection 25mg/m2, carboplatin AUC 5, first day, intravenous drip, repeated every three weeks.</description>
    <arm_group_label>PP</arm_group_label>
    <other_name>PP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel +carboplatin</intervention_name>
    <description>paclitaxel 175mg/m2, carboplatin AUC 5, day 1, intravenous infusion, repeated every three weeks.</description>
    <arm_group_label>TP</arm_group_label>
    <other_name>TP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age: 18-75 years old

          2. PS score: ECOG 0 ~ 2

          3. histopathologically confirmed primary high-grade serous adenocarcinoma or high-grade
             endometrioid adenocarcinoma of the ovary, fallopian tube or peritoneum;

          4. the time interval between this recurrence and the last chemotherapy was 6-12 months;

          5. evaluate the ability of bone marrow, liver, kidney, heart and other important organ
             functions to withstand chemotherapy;

          6. expected survival over 3 months;

          7. sign the informed consent.

        Exclusion Criteria:

          1. brain metastasis or the presence of symptoms caused by brain metastasis;

          2. serious complications;

          3. acute inflammatory reaction;

          4. other tumors;

          5. a history of allergy to paclitaxel or polyropyridone liposomes;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Wang, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Wang, MD.</last_name>
    <phone>（86-0731）88651849</phone>
    <email>wangjing@hnca.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Su, MD.</last_name>
    <phone>（86-0731）89762815</phone>
    <email>sujing@hnca.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Wang, MD.</last_name>
      <phone>(86-0731)88651849</phone>
      <email>wangjing@hnca.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Su, MD.</last_name>
      <phone>(86-0731)89762815</phone>
      <email>sujing@hnca.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>JingWang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

